ReviewFrontiers in medicine2024
Biases in COVID-19 vaccine effectiveness studies using cohort design.
Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Most COVID-19 vaccine adverse events detected within 48 hours in Ethiopia: implications for cohort event monitoring efficiency in resource-limited settings.European journal of clinical pharmacology · 2026Article
- Considerations for assessing the feasibility of network meta-analysis of seasonal vaccines.Journal of comparative effectiveness research · 2026Article
- Dynamics of infection, vaccination and excess mortality during the COVID-19 pandemic among older individuals-a nationwide analysis.European journal of epidemiology · 2026Article
- Optimizing the sensitivity of detection of respiratory syncytial virus infections in longitudinal studies using the combination of weekly sample testing and biannual serology.American journal of epidemiology · 2026Article
- Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals.JAMA network open · 2026Article
- Effectiveness of COVID-19 Vaccine Boosters in Children Across Pandemic and Endemic Periods.Microorganisms · 2026Article
- Age-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities: an exploratory analysis.Frontiers in public health · 2026Observational
- SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study.Epidemiologia (Basel, Switzerland) · 2025Article
- Ophthalmic complications associated with COVID-19: a large US national database analysis.Eye (London, England) · 2025Article
- Disease and Economic Burden Averted by Hib Vaccination in 160 Countries: A Machine-Learning Analysis.Vaccines · 2025Article
- Optimizing the sensitivity of detection of respiratory syncytial virus infections in longitudinal studies using the combination of weekly sample testing and biannual serology.medRxiv : the preprint server for health sciences · 2025Article
- BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5-11 years in Scotland.Journal of global health · 2025Article
- Effectiveness of a Covid mRNA Vaccine Against Two Early Variants: A Reanalysis of Published Data.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observational studies on COVID-19 vaccine effectiveness (VE) have provided critical real-world data, informing public health policy globally. These studies, primarily using pre-existing data sources, have been indispensable in assessing VE across diverse populations and developing sustainable vaccination strategies. Cohort design is frequently employed in VE research. The rapid implementation of vaccination campaigns during the COVID-19 pandemic introduced differential vaccination influenced by sociodemographic disparities, public policies, perceived risks, health-promoting behaviors, and health status, potentially resulting in biases such as healthy user bias, healthy vaccinee effect, frailty bias, differential depletion of susceptibility bias, and confounding by indication. The overwhelming burden on healthcare systems has escalated the risk of data inaccuracies, leading to outcome misclassifications. Additionally, the extensive array of diagnostic tests used during the pandemic has also contributed to misclassification biases. The urgency to publish quickly may have further influenced these biases or led to their oversight, affecting the validity of the findings. These biases in studies vary considerably depending on the setting, data sources, and analytical methods and are likely more pronounced in low- and middle-income country (LMIC) settings due to inadequate data infrastructure. Addressing and mitigating these biases is essential for accurate VE estimates, guiding public health strategies, and sustaining public trust in vaccination programs. Transparent communication about these biases and rigorous improvement in the design of future observational studies are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.